Physician profile
William Lee Bell
NPI 1619971694
$2,145.50
in general payments reported to CMS, 2019-2025
22 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $627 · 2021: $553 · 2022: $268 · 2023: $109 · 2024: $289 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $387.63 | 2020-2024 | Rybelsus, Ozempic |
| Organogenesis INC. | $274.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $107.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $97.39 | 2020 | |
| Amarin Pharma, INC. | $83.87 | 2020-2022 | |
| Pfizer INC. | $77.50 | 2020-2025 | |
| Esperion Therapeutics, INC. | $73.85 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $61.40 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $60.95 | 2022 | |
| Glaxosmithkline, LLC. | $60.91 | 2020-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $44.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Averitas Pharma INC. | $31.80 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.74 | 2024 | Trulance, Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $27.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.34 | 2019-2020 | |
| Eisai INC. | $19.34 | 2021 | |
| Medtronic Minimed, INC. | $18.18 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.40 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.27 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.